RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionASCO 2024 poster conclusions support the previous post's observations that external TiLs therapy is not required with ONCY's pelareorep in order to gain the same advantages of T cell expansion and tumor killing effect.. To quote:
"These findings, while preliminary, suggest that the clinical benefits observed following pela immunotherapy may be mechanistically analogous to ACT. Accordingly, pela therapy may offer a means to directly expand TILs without the need for tumor resection, ex vivo TIL expansion, T cell ablation and IL-2 therapy. "